What is SER's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SER?

P/E (TTM) is n/a and 52-week range is $1.22 to $5.71 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SER figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SER?

The company profile lists revenue (TTM) near $144K, net income (TTM) near $-504M, EPS (TTM) near $-1.14 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Serina Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Huntsville, Alabama, US, 15M shares outstanding, ISIN US81751A1088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Serina Therapeutics Inc

$SER

Health Care · Biotechnology

IR Run Scenarios

$2.00

-0.50%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 16 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.

Employees

Website

serinatherapeutics.com/

IPO

2018-11-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)